

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10567594
	Filing Date		2006-12-12
	First Named Inventor	Elisabeth Arkenau-Maric	
	Art Unit	1615	
	Examiner Name	Hasen Syed Ahmed	
	Attorney Docket Number	107101-47	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4690822	A	1987-09-01	UEMURA ET AL.	
	2	5051261	A	1991-09-24	MCGINITY ET AL.	
	3	6348469	B1	2002-02-19	SETH	
	4	6375963	B1	2002-04-23	REPKA ET AL.	
	5	6399100	B1	2002-06-04	CLANCY ET AL.	
	6	6562375	B1	2003-05-13	SAKO ET AL.	
	7	6753009	B2	2004-06-22	LUBER ET AL.	
	8	5620697	A	1997-04-15	TORMALA ET AL.	corresponds to JP 8 505076

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10567594
Filing Date		2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric	
Art Unit		1615
Examiner Name	Hasen Syed Ahmed	
Attorney Docket Number		107101-47

	9	6290990	B1	2001-09-18	GRABOWSKI ET AL.	
	10	5741519	A	1998-04-21	ROSENBERG ET AL.	
	11	5939099	A	1999-08-17	GRABOWSKI ET AL.	
	12	6120802	A	2000-09-19	BREITENBACH ET AL.	
	13	6001391	A	1999-12-14	ZEIDLER ET AL.	
	14	6318650	B1	2001-11-20	BREITENBACH ET AL.	
	15	4880585	A	1989-11-14	KLIMESCH ET AL.	
	16	4957668	A	1990-09-18	PLACKARD ET AL.	
	17	5562920	A	1996-10-08	DEMME ET AL.	
	18	6821588	B1	2004-11-23	HAMMER ET AL.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number		10567594
Filing Date		2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric	
Art Unit		1615
Examiner Name	Hasen Syed Ahmed	
Attorney Docket Number		107101-47

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040052844	A1	2004-03-18	HSIAO ET AL.	
	2	20050095291	A1	2005-05-05	BENJAMIN OSHLACK ET AL.	
	3	20030125347	A1	2003-07-03	ANDERSON ET AL.	
	4	20070269505	A1	2007-11-22	FLATH ET AL.	
	5	20020132359	A1	2002-09-19	WATERMAN	

If you wish to add additional U.S. Published Application citation information please click the Add button.

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0544144	EP	A1	1993-06-02	BASF AG	English abstract enclosed	<input type="checkbox"/>
	2	0636370	EP	A1	1995-02-01	EURO CELTIQUE SA		<input type="checkbox"/>
	3	0647448	EP	A1	1995-04-12	EURO CELTIQUE SA		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10567594
Filing Date		2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric	
Art Unit	1615	
Examiner Name	Hasen Syed Ahmed	
Attorney Docket Number	107101-47	

	4	0675710	EP	A1	1995-10-11	SAITEC SRL	corresponds to US 5662935 A	<input type="checkbox"/>
	5	0756480	EP	A1	1997-02-05	BASF AG	corresponds to US 6290990 B1	<input type="checkbox"/>
	6	0760654	EP	A1	1997-03-12	BASF AG	corresponds to US 5741519 A	<input type="checkbox"/>
	7	0785775	EP	A1	1997-07-30	EURO CELTIQUE SA	corresponds to US 5958452 A	<input type="checkbox"/>
	8	0809488	EP	A1	1997-12-03	BASF AG	corresponds to US 5,939,099	<input type="checkbox"/>
	9	0857062	EP	A2	1998-08-12	BASF AG	corresponds to US 6,120,802	<input type="checkbox"/>
	10	0864324	EP	A1	1998-09-16	BASF AG	corresponds to US 6,001,391	<input type="checkbox"/>
	11	0864326	EP	A2	1998-09-16	KNOLL AG	English abstract attached	<input type="checkbox"/>
	12	0988106	EP	A1	2000-03-29	BASF AG	corresponds to US 6,318,650	<input type="checkbox"/>
	13	1014941	EP	A1	2000-07-05	UNIV TEXAS		<input type="checkbox"/>
	14	1293196	EP	A2	2003-03-19	PHARMA PASS II LLC		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10567594
Filing Date		2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric	
Art Unit		1615
Examiner Name	Hasen Syed Ahmed	
Attorney Docket Number		107101-47

15	1527775	EP	A1	2005-04-05	EURO CELTIQUE SA		<input type="checkbox"/>
16	02/088217	WO	A1	2002-11-07	UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORP		<input type="checkbox"/>
17	03/026624	WO	A1	2003-04-03	MCNEIL-PPC, INC		<input type="checkbox"/>
18	03/028990	WO	A1	2003-04-10	MCNEIL-PPC, INC		<input type="checkbox"/>
19	03/035177	WO	A2	2003-05-01	DEPOMED, INC.		<input type="checkbox"/>
20	03/092648	WO	A1	2003-11-13	ALZA CORPORATION		<input type="checkbox"/>
21	04/066910	WO	A2	2004-08-12	GLENMARK PHARMACEUTICALS LTD.		<input type="checkbox"/>
22	04/084869	WO	A1	2004-10-07	EGALET AS		<input type="checkbox"/>
23	04/093801	WO	A2	2004-11-04	EURO-CELTIQUE S.A..		<input type="checkbox"/>
24	04/100894	WO	A2	2004-11-25	SHIRE LABORATORIES, INC.		<input type="checkbox"/>
25	05/032524	WO	A2	2005-04-14	ALZA CORPORATION		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10567594
Filing Date		2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric	
Art Unit		1615
Examiner Name	Hasen Syed Ahmed	
Attorney Docket Number		107101-47

	26	05/065646	WO	A2	2005-04-14	ALZA CORPORATION		<input type="checkbox"/>
	27	0240906	EP	A2	1987-10-14	BASF AG	corresponds to US 4880585 A	<input type="checkbox"/>
	28	2003026743	WO	A2	2003-04-03	Penwest Pharmaceuticals Company		<input type="checkbox"/>
	29	05/053587	WO	A1	2005-06-16	ACURA PHARMACEUTICALS INC		<input type="checkbox"/>
	30	05/055981	WO	A2	2005-06-23	EURO CELTIQUE SA		<input type="checkbox"/>
	31	90/003776	WO	A1	1990-04-19	ZETACHRON INC		<input type="checkbox"/>
	32	09/135680	WO	A1	2009-11-12	GRUENENTHAL GMBH		<input type="checkbox"/>
	33	09/092601	WO	A1	2009-07-30	GRUENENTHAL GMBH		<input type="checkbox"/>
	34	07/085024	WO	A2	2007-07-26	ABBOTT GMBH & CO KG		<input type="checkbox"/>
	35	07/005716	WO	A2	2007-01-11	CINERGEN LLC		<input type="checkbox"/>
	36	03-501737	JP	A	1991-04-18	ZETACHRON INC	corresponds to English-language equivalent WO 90/003776	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10567594
Filing Date	2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric
Art Unit	1615
Examiner Name	Hasen Syed Ahmed
Attorney Docket Number	107101-47

37	04/004693	WO	A1	2004-01-15	COLLGEGIUM PHARMACEUTICAL		<input type="checkbox"/>
38	19800689	DE	C1	1999-07-15	DELORO STELLITE GMBH	abstract is attached	<input type="checkbox"/>
39	8-505076	JP	A	1996-06-04	Tormala et al	Corresponds to US 5620697. A copy is provided.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Maggi. Therapeutic Potential of Capsaicin-like Molecules. 1Life Sciences, Vol. 51, pp. 1777-1781, 1992.	<input type="checkbox"/>
	2	Handbuch der Kunststoff-Extrusionstechnik 1, "Grundlagen" in Chapter 1.2 "Klassifizierung von Extrudern", pgs 3-7. 1989.	<input checked="" type="checkbox"/>
	3	2.9 Methoden der pharmazeutischen Technologie 143-144, 1997.	<input checked="" type="checkbox"/>
	4	Dachille, F. et al., "High-Pressure Phase Transformation in Laboratory Mechanical Mixers and Mortars", 1960., Nature, 186, pp. 1-2 (abstract)	<input type="checkbox"/>
	5	Freed et al. pH control of nucleophilic/electrophilic oxidation. International Journal of Pharmaceutics. 2008, Vol 357, Pages 180-188.	<input type="checkbox"/>
	6	Waterman et al. Stabilization of Pharmaceuticals to Oxidative Degradation. Pharmaceutical Development and Technology. 2002, Vol 7, No. 1, Pages 1-32.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10567594
Filing Date		2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric	
Art Unit	1615	
Examiner Name	Hasen Syed Ahmed	
Attorney Docket Number	107101-47	

7	Maggi, L. et al., "High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage form", 2000, International Journal of Pharmaceutics, 195 pp, 229-238	<input type="checkbox"/>
8	Conversion of 18.8 kiloponds to newtons, <a href="http://www.unitconversion.org/force/newtons-to-kiloponds-conversion.html">http://www.unitconversion.org/force/newtons-to-kiloponds-conversion.html</a> on July 5, 2011	<input type="checkbox"/>
9	Waltimo et al. A novel bite force recorder and maximal isometric bite force values for healthy young adults. Scand J Dent Res. 1993, Vol 101, Pages 171-5.	<input type="checkbox"/>
10	Waltimo et al. Maximal bite force and its association with signs and symptoms of craniomandibular disorders in young Finnish non-patients. Acta Odonol. Scand. 1995, Vol 53, Pages 254-258.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10567594
Filing Date	2006-12-12
First Named Inventor	Elisabeth Arkenau-Maric
Art Unit	1615
Examiner Name	Hasen Syed Ahmed
Attorney Docket Number	107101-47

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ A certification statement is not submitted herewith.

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Kurt G. Briscoe/	Date (YYYY-MM-DD)	2011-10-06
Name/Print	Kurt G. Briscoe	Registration Number	33141

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.